• Publications
  • Influence
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
TLDR
Rates of response to a 12-week interferon-free combination regimen were more than 95% among previously treated patients with HCV genotype 1 infection, including patients with a prior null response.
Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α‐2a (40 kd)/ribavirin therapy
TLDR
Patients infected with HCV genotype 1 and treated with peginterferon α‐2a/ribavirin sustained a RVR 24% of the time, which portends an 89% probability of a SVR after 24 weeks of treatment.
Epidemiology of hepatitis B and C viruses: a global overview.
TLDR
The transmission of hepatitis C has been greatly impacted by mandatory screening of blood donors in most countries in the world, although intravenous drug use continues to be a major source of infection.
A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus.
TLDR
A meta-analysis of observational cohort studies that followed HCV treatment failure patients with advanced fibrosis found that achieving a sustained viral response (SVR) is associated with substantially lower liver-related morbidity and mortality.
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2
TLDR
The findings lend support to the further assessment of sofosbuvir 400 mg plus peginterferon and ribavirin for 12 weeks in treatment-naive patients with HCV genotype-1, and sustained virological response, defined as undetectable HCV RNA at post-treatment weeks 12 and 24.
Re-treatment of Patients With Chronic Hepatitis C Who Do Not Respond to Peginterferon-2b
TLDR
Re-treating the nonresponders for 72 weeks increased sustained virologic response rates more than did re-treatment for 48 weeks, although the rates remained disappointingly low in these patients.
Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C.
TLDR
Once-weekly PEG(40kd) IFN alpha-2a was associated with a higher number of sustained virological responses compared with IFNAlpha2a 3 times weekly in patients with CHC, but had a similar safety profile.
Efficacy and safety of pegylated (40‐kd) interferon α‐2a compared with interferon α‐2a in noncirrhotic patients with chronic hepatitis C
TLDR
Once‐weekly PEG(40kd) IFN α‐2a was associated with a higher number of sustained virological responses compared with IFNalpha 3 times weekly in patients with chronic hepatitis C, but had a similar safety profile.
Predictive value of ALT levels for non‐alcoholic steatohepatitis (NASH) and advanced fibrosis in non‐alcoholic fatty liver disease (NAFLD)
Non‐alcoholic fatty liver disease (NAFLD) patients with elevated serum alanine aminotransferase (ALT) generally undergo a liver biopsy to evaluate for possible non‐alcoholic steatohepatitis (NASH) or
Current state of combined heart-liver transplantation in the United States.
TLDR
Combined heart-liver transplantation is a viable option for candidates who require the combined transplantation, with outcomes comparable to those of single-organ recipients.
...
1
2
3
4
5
...